Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANA MEREDITH CHASE

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecologic Oncology

NPI
1396888947
CMS profile
290086
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$144,892.79

99 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $56,630.09 41
AstraZeneca Pharmaceuticals LP $40,323.34 16
Eisai Inc. $14,124.40 12
ABBVIE INC. $11,921.47 11
PFIZER INC. $8,640.00 2
Daiichi Sankyo Inc. $7,260.41 11
Corcept Therapeutics $3,315.06 3
AstraZeneca UK Limited $2,548.09 2
INTUITIVE SURGICAL, INC. $129.93 1

Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANA MEREDITH CHASE

NPI 1396888947 · CMS profile ID 290086

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecologic Oncology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396888947?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANA MEREDITH CHASE, NPI 1396888947, CMS profile ID 290086. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396888947?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DANA MEREDITH CHASE, NPI 1396888947, CMS profile ID 290086. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396888947?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DANA MEREDITH CHASE, NPI 1396888947, CMS profile ID 290086, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1396888947?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

99 matching records · $144,892.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 99 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–99 of 99.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $124.0306/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191838324 CMS
Eisai Inc. $400.1106/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244473652 CMS
Eisai Inc. $100.4706/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244473644 CMS
Eisai Inc. $2,037.5006/25/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1244473646 CMS
Eisai Inc. $815.0006/25/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1244473648 CMS
PFIZER INC. $720.0006/12/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1231717158 CMS
ABBVIE INC. $219.9906/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201638013 CMS
GlaxoSmithKline, LLC. $1,635.2206/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1190483034 CMS
GlaxoSmithKline, LLC. $818.3106/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1191183836 CMS
ABBVIE INC. $46.3706/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201638011 CMS
Corcept Therapeutics $15.0606/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214241100 CMS
ABBVIE INC. $43.0006/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201638009 CMS
GlaxoSmithKline, LLC. $1,000.0005/30/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1191525141 CMS
GlaxoSmithKline, LLC. $3,200.0005/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1191015958 CMS
GlaxoSmithKline, LLC. $4,800.0005/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1191737534 CMS
GlaxoSmithKline, LLC. $50.0005/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1190654436 CMS
GlaxoSmithKline, LLC. $2,000.0005/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1191117211 CMS
AstraZeneca Pharmaceuticals LP $362.5805/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242510796 CMS
GlaxoSmithKline, LLC. $117.3104/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191245272 CMS
GlaxoSmithKline, LLC. $751.6604/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1191780952 CMS
GlaxoSmithKline, LLC. $661.8804/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1191141650 CMS
GlaxoSmithKline, LLC. $122.0604/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190608111 CMS
GlaxoSmithKline, LLC. $349.6404/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1190981623 CMS
GlaxoSmithKline, LLC. $233.7404/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1191407099 CMS
AstraZeneca Pharmaceuticals LP $6,560.0004/15/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1242509400 CMS
AstraZeneca Pharmaceuticals LP $4,920.0004/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1242509320 CMS
AstraZeneca Pharmaceuticals LP $430.4404/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242508988 CMS
AstraZeneca Pharmaceuticals LP $112.4404/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242509534 CMS
GlaxoSmithKline, LLC. $3,200.0004/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1191560731 CMS
AstraZeneca Pharmaceuticals LP $6,560.0003/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1242511350 CMS
AstraZeneca Pharmaceuticals LP $1,640.0003/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1242511584 CMS
AstraZeneca Pharmaceuticals LP $665.1203/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242509578 CMS
AstraZeneca Pharmaceuticals LP $115.5203/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242510254 CMS
Corcept Therapeutics $2,200.0003/26/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1214241088 CMS
AstraZeneca Pharmaceuticals LP $296.9603/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242510876 CMS
GlaxoSmithKline, LLC. $2,400.0003/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1190720854 CMS
GlaxoSmithKline, LLC. $46.6703/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190538604 CMS
GlaxoSmithKline, LLC. $34.1803/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191366568 CMS
ABBVIE INC. $138.7603/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201638007 CMS
GlaxoSmithKline, LLC. $122.8803/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190777172 CMS
GlaxoSmithKline, LLC. $780.7203/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1191064543 CMS
AstraZeneca Pharmaceuticals LP $89.0303/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242509642 CMS
AstraZeneca Pharmaceuticals LP $831.3903/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242511688 CMS
GlaxoSmithKline, LLC. $50.0002/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1191334740 CMS
ABBVIE INC. $120.8501/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201638005 CMS
AstraZeneca Pharmaceuticals LP $50.8601/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206483724 CMS
AstraZeneca Pharmaceuticals LP $54.0001/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206299650 CMS
PFIZER INC. $7,920.0001/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1231121972 CMS
GlaxoSmithKline, LLC. $1,600.0001/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1190797763 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $287,401.65 290
PY2020 $102,429.83 75
PY2021 $100,131.71 70
PY2022 $181,662.00 124
PY2023 $253,425.55 170
PY2024 $219,218.10 141
PY2025 $144,892.79 99

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $431,331.21 5
PY2024 Principal investigator $12,585.28 2
PY2023 Principal investigator $27,872.80 2
PY2022 Principal investigator $14,720.00 6
PY2021 Principal investigator $255,839.70 20
PY2020 Principal investigator $113,891.00 19
PY2019 Principal investigator $658,008.20 53

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

5 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $132,344.96 12/31/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A phase I/II trial of the integration of radiotherapy into chemotherapy with pembrolizumab/bevacizumab in newly diagnosed Stage IVB cervical cancer No dispute reported 06/30/2026 1232935537
Principal investigator 1 Merck Sharp & Dohme LLC $4,681.50 08/31/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemoth No dispute reported 06/30/2026 1232923012
Principal investigator 1 Merck Sharp & Dohme LLC $249,734.75 08/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A phase I/II trial of the integration of radiotherapy into chemotherapy with pembrolizumab/bevacizumab in newly diagnosed Stage IVB cervical cancer No dispute reported 06/30/2026 1232935535
Principal investigator 1 ABBVIE INC. $37,520.00 07/28/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression No dispute reported 06/30/2026 1202420428
Principal investigator 1 ABBVIE INC. $7,050.00 07/28/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression No dispute reported 06/30/2026 1202420431